AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...

Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the world understands ultra-processed foods, after more than 90 independent food ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...

Novo Nordisk is developing Amycretin, a pill-form GLP-1 agonist that could attract more patients than existing injectable products. Although the GLP-1 agonist opportunity is still nascent ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...